Non-invasive imaging of the type 2 cannabinoid receptor, focus on positron emission tomography

Current Topics in Medicinal Chemistry

Volumn 10, Issue 15, 2010, Pages 1527-1543

  Evens, Nele ^a   Bormans, Guy M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Endocannabinoid; Non invasive imaging; PET; Type 2 cannabinoid receptor

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID DERIVATIVE; CARBON 11; CYCLOOXYGENASE 1; ENDOCANNABINOID; FLUORINE 18; FLUORO DELTA 9 TETRAHYDROCANNABINOL F 18; FLUOROETHYL 1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE C 11; FLUOROETHYL 1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE F 18; GW 842166; INDOLE DERIVATIVE; MBC 94; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NITROGEN; OXYGEN 18; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; RIMONABANT; SCH 225336; SCH 225336 C 11; SCH 225336 S 35; SR 144385; SR 144385 F 18; TETRAHYDROCANNABINOL DERIVATIVE; TRIARYL BISULFONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; ALLERGIC ENCEPHALOMYELITIS; AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIC ACTIVITY; ARTICLE; AUTOPSY; B LYMPHOCYTE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CANCER THERAPY; CELL ACTIVATION; DEPRESSION; DOWN SYNDROME; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; ENANTIOMER; FOOD INTAKE; GLIA CELL; GLIOSIS; HUMAN; HUNTINGTON CHOREA; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; IMMUNOREGULATION; MICROGLIA; MULTIDRUG RESISTANCE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPROTECTION; NON INVASIVE MEASUREMENT; NONHUMAN; OBESITY; OXIDATIVE STRESS; PAIN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOCHEMISTRY; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SPECTRAL SENSITIVITY; STEREOTACTIC TREATMENT; TUMOR GROWTH;

EID: 77958011594     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610793176819     Document Type: Article

References (151)

1. Gaoni, Y.; Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc., 1964, 86, 1646.
2. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-564.
3. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
4. Di Marzo, V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol. Sci., 2006, 27, 134-140.
5. Zimmer, A.; Zimmer, A.M.; Hohmann, A.G.; Herkenham, M.; Bonner, T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA, 1999, 96, 5780-5785.
6. Buckley, N.E. The peripheral cannabinoid receptor knockout mice: an update. Br. J. Pharmacol., 2008, 153, 309-318.
7. Buckley, N.E.; McCoy, K.L.; Mezey, E.; Bonner, T.; Zimmer, A.; Felder, C.C.; Glass, M.; Zimmer, A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur. J. Pharmacol., 2000, 396, 141-149.
8. Ziring, D.; Wei, B.; Velazquez, P.; Schrage, M.; Buckley, N.E.; Braun, J. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics, 2006, 58, 714-725.
9. Julien, B.; Grenard, P.; Teixeira-Clerk, F.; Tran Van Nhiew, J.; Li, L.; Karsak, M.; Zimmer, A.; Mallat, A.; Lotersztajn, S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology, 2005, 128, 742-755.
10. Ibrahim, M.M.; Rude, M.L.; Stagg, N.J.; Mata, H.P.; Lai, J.; Vanderah, T.W.; Porreca, F.; Buckley, N.E.; Makriyannis, A.; Malan, T.P.Jr. CB2 cannabinoid receptor mediation of antinociception. Pain, 2006, 122, 36-42.
11. Maresz, K.; Pryce, G.; Ponomarev, E.D.; Marsicano, G.; Croxford, L.; Shriver, L.P.; Ledent, C.; Cheng X.; Carrier E.J.; Mann M.K.; Giovannoni G.; Pertwee R.G.; Yamamura T.; Buckley N.E.; Hillard C.J.; Lutz B.; Baker D.; Dittel B.N. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med., 2007, 13, 492-497.
12. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K.; Tam, J.; Attar-Namdar, M.; Kram, V.; Shohami, E.; Mechoulam, R.; Zimmer, A.; Bab, I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. USA, 2006, 103, 696-701.
13. Sawzdargo, M.; Nguyen, T.; Lee, D.K.; Lynch, K.R.; Cheng, R.; Heng, H.; George, S.R.; O'Dowd, B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, GPR53 and GPR55: GPR55 is extensively expressed in human brain. Mol. Brain Res.,1999, 64, 193-198.
14. Ryberg, E.; Larsson, N.; Sjögren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152, 1092-1101.
15. Pietr, M.; Kozela, E.; Levy, R.; Rimmerman, N.; Lin, Y.H.; Stella, N.; Vogel, Z.; Juknat, A. Differential changes in GPR55 during microglial cell activation. FEBS Lett., 2009, 583, 2071-2076.
16. Milligan, G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol. Pharmacol., 2003, 64, 1271-1276.
17. Pertwee, R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci., 2005, 76, 1307-1324.
18. Szabo, B. Pharmacology of cannabinoid receptors. Biotrend Rev., 2008, 2, 1-13.
19. Mukherjee, S.; Adams, M.; Whiteaker, K.; Daza, A.; Kage, K.; Cassar, S.; Meyer, M.; Yao, B.B. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur. J. Pharmacol., 2004, 505, 1-9.
20. Shire, D.; Calandra, B.; Rinaldi-Carmona, M.; Oustric, D.; Pessègue, B.; Bonnin-Cabanne, O.; Le Fur, G.; Caput, D.; Ferrara, P. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim. Biophys. Acta, 1996, 1307, 132-136.
21. Chakrabarti, A.; Onaivi, E.S.; Chaudhuri, G. Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Seq., 1995, 5, 385-388.
22. Lynn, A.B.; Herkenham, M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther., 1994, 268, 1612-1623.
23. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232, 54-61.
24. Carayon, P.; Marchand, J.; Dussossoy, D.; Derocq, J.M.; Jbilo, O.; Bord, A.; Bouaboula, M.; Galiege, S.; Mondiere, P.; Penarier, G.; Le Fur, G.; Defrance, T.; Casellas, P. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood, 1998, 92, 3605-3615.
25. Carlisle, S.J.; Marciano-Cabral, A.; Staab, A.; Ludwick, C.; Cabral, G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol., 2002, 2, 69-82.
26. Schatz, A.R.; Lee, M.; Condie, R.B.; Pulaski, J.T.; Kaminski, N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol., 1997, 142, 278-287.
27. Govaerts, S.J.; Hermans, E.; Lambert, D.M. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur. J. Pharm. Sci., 2004, 23, 233-243.
28. Cavuoto, P.; McAinch, A.J.; Hatzinikolas, G.; Janovska, A.; Game, P.; Wittert, G.A. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem. Biophys. Res. Commun., 2007, 364, 105-110.
29. Bermudez-Silva, F.J.; Sanchez-Vera, I.; Suarez, J.; Serrano, A.; Fuentes, E.; Juan-Pico, P.; Nadal, A.; Rodriguez de Fonseca, F. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur. J. Pharmacol., 2007, 565, 207-211.
30. Bermudez-Silva, Suarez J.; Baixeras, E.; Cobo, N.; Bautista, D.; Cuesta-Munoz, A.L.; Fuentes, E.; Juan-Pico, P.; Castro, M.J.; Milman, G.; Mechoulam, R.; Nadal, A.; Rodriguez de Fonseca, F. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologica, 2008, 51, 476-487.
31. El-Talatini, M.R.; Taylor, A.H.; Elson, J.C.; Brown, L.; Davidson, A.C.; Konje, J.C. Localisation and function of the endocannabinoid system in the human ovary. Plos One, 2009, 4, e4579.
32. Weis, F.; Beiras-Fernandez, A.; Sodian, R.; Kaczmarek, I.; Reichart, B.; Beiras, A.; Schelling, G.; Kreth, S. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J. Mol. Cell. Cardiol., 2010, 48(6), 1187-1193.
33. Van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J.S.; Marnett, L.J.; Di Marzo, V.; Pittman, Q.J.; Patel, K.D.; Sharkey, K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 2005, 310, 329-332.
34. Gong, J.; Onaivi, E.S.; Ishiguro, H.; Liu, Q.; Tagliaferro, P.A.; Brusco, A.; Uhl, G.R. Cannabinoid CB2 receptors: immunohisto-chemical localization in rat brain. Brain Res., 2006, 1071, 10-23.
35. Ashton, J.C.; Friberg, D.; Darlington, C.L.; Smith, P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immuno-histochemical study. Neurosci. Lett., 2006, 396, 113-116.
36. Liu, Q.R.; Pan, C.; Hishimoto, A.; Li, C.; Xi, Z.; Llorente-Berzal, A.; Viveros, M.; Ishiguro, H.; Arinami, T.; Onaivi, E.S.; Uhl, G.R. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav., 2009, 8, 519-530.
37. Morgan, N.H.; Stanford, I.M.; Woodhall, G.L. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology, 2009, 57, 356-368.
38. Páldy, E.; Bereczki, E.; Sántha, M.; Wenger, T.; Borsodi, A.; Zimmer, A.; Benyhe, S. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. Neurochem. Int., 2008, 53, 309-316.
39. Fernandez-ruiz, J.; Gonzalez, S.; Romero, J.; Ramos, J.A. Cannabinoids in neurodegeneration and neuroprotection. In: Cannabinoids as Therapeutics; Mechoulam, R.; Ed.; Birkhauser Verlag Switzerland, 2005, pp 79-109.
40. Onaivi, E.S.; Carpio, O.; Ishiguro, H.; Schanz, N.; Uhl, G.R.; Benno, R. Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann. N. Y. Acad. Sci., 2008, 1139, 426-433.
41. Onaivi, E.S.; Ishiguro, H.; Gong, J.; Patel, S.; Meozzi, P.A.; Myers, L.; Perchuk, A.; Mora, Z.; Tagliaferro, P.A.; Gardner, E.; Brusco, A.; Akinshola, B.E.; Liu, Q.; Chirwa, S.; Hope, B.; Lujilde, J.; Inada, T.; Iwasaki, S.; Macharia, D.; Teasenfitz, L.; Arinami, T.; Uhl, G.R. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann. N. Y. Acad. Sci., 2008, 1139, 434-449.
42. Ishiguro, H.; Horiuchi, Y.; Ishikawa, M.; Koga, M.; Imai, K.; Suzuki, Y.; Morikawa, M.; Inada, T.; Watanabe, Y.; Takahashi, M.; Someya, T.; Ujike, H.; Iwata, N.; Ozaki, N.; Onaivi, E.S.; Kunugi, H.; Sasaki, T.; Itokawa, M.; Arai, M.; Niizato, K.; Iritani, S.; Naka, I.; Ohashi, J.; Kakita, A.; Takahashi, H.; Nawa, H.; Arinami, T. Brain cannabinoid CB2 receptor in schizophrenia. Biol. Psychiatry, 2010, 67(10), 974-982.
43. Sanchez, C.; de Ceballos, M.L.; Gomez del Pulgar, T.; Rueda, D.; Corbacho, C.; Velasco, G.; Galve-Roperh, I.; Huffman, J.W.; Ramóny Cajal, S.; Guzmán, M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res., 2001, 61, 5784-5789.
44. McKallip, R.J.; Lombard, C.; Fisher, M.; Martin, B.R.; Ryu, S.; Grant, S.; Nagarkatti, P.S.; Nagarkatti, M. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood, 2002, 100, 627-634.
45. Alexander, A.; Smith, P.F.; Rosengren, R.J. Cannabinoids in the treatment of cancer. Cancer Lett., 2009, 285, 6-12.
46. Ellert-Miklaszewska, A.; Grajkowska, W.; Gabrusiewicz, K.; Kaminska, B.; Konarska, L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res., 2007, 1137, 161-169.
47. Calatozzolo, C.; Salmaggi, A.; Pollo, B.; Sciacca, F.L.; Lorenzetti, M.; Franzini, A.; Boiardi, A.; Broggi, G.; Marras, C. Expression of cannabinoid receptors and neutrophins in human gliomas. Neurol. Sci., 2007, 28, 304-310.
48. Casanova, M.L.; Blazquez, C.; Martinez-Palacio, J.; Villanueva, C.; Fernandez-Acenero, M.J.; Huffman, J.W.; Jorcano, J.L.; Guzman, M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest., 2003, 111, 43-50.
49. Zheng, D.; Bode, A.M.; Zhao, Q.; Cho, Y.; Zhu, F.; Ma, W.; Dong, Z. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res., 2008, 68, 3992-3998.
50. Qamri, Z.; Preet, A.; Nasser, M.W.; Bass, C.E.; Leone, G.; Barsky, S.H.; Ganju, R.K. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol. Cancer. Ther., 2009, 8, 3117-3129.
51. Steffens, S.; Veillard, N.R.; Arnaud, C.; Pelli, G.; Burger, F.; Staub, C.; Zimmer, A.; Frossard, J.; Mach, F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 2005, 434, 782-786.
52. Iuvone, T.; De Filippis, D.; Di Spiezio Sardo, A.; D'Amico, A.; Simonetti, S.; Sparice, S.; Esposito, G.; Bifulco, G.; Insabato, L.; Nappi, C.; Guida, M. Selective CB2 up-regulation in women affected by endometrial inflammation. J. Cell. Mol. Med., 2008, 12, 661-670.
53. Klein, T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol., 2005, 5, 400-411.
54. Wojtera, M.; Sikorska, B.; Sobow, T.; Liberski, P.P. Microglial cells in neurodegenerative disorders. Folia Neuropathol., 2005, 43, 311-321.
55. Maresz, K.; Carrier, E.J.; Ponomarev, E.D.; Hillard, C.J.; Dittel, B.N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem., 2005, 95, 437-445.
56. Cabral, G.A.; Marciano-Cabral, F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol., 2005, 78, 1192-1197.
57. Fernandez-Ruiz, J.J.; Romero, J.; Velasco, G.; Tolon, R.M.; Ramos, J.A.; Guzman, M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival. Trends Pharmacol. Sci., 2007, 28, 39-45.
58. Benito, C.; Nunez, E., Tolon, R.M.; Carrier, E.J.; Rabano, A.; Hillard, C.J., Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci., 2003, 23, 11136-11141.
59. Tolon, R.M.; Nunez, E.; Pazos, M.R.; Benito, C.; Castillo, A.I.; Martinez-Orgado, J.A.; Romero, J. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res., 2009, 1283, 148-154.
60. Nunez, E.; Benito, C.; Tolon, R.M.; Hillard, C.J.; Griffin, W.S.T.; Romero, J. Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience, 2008, 151, 104-110.
61. Yiangou, Y.; Facer, P.; Durrenberger, P.; Chessell, I.P.; Naylor, A.; Bountra, C.; Banati, R.R.; Anand, P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol., 2006, 6, 12.
62. Palazuelos, J.; Davoust, N.; Julien, B.; Hatterer, E.; Aguado, T.; Mechoulam, R.; Benito, C.; Romero, J.; Silva, A.; Guzman, M.; Nataf, S.; Galve-Roperh, I. The CB2 cannabinoid receptor controls myeloid progenitor trafficking. J. Biol. Chem., 2008, 283, 13320-13329.
63. Papadopoulos, V.; Baraldi, M.; Guilarte, T.R.; Knudsen, T.B.; Lacapere, J.J.; Lindemann, P.; Norenberg, M.D.; Nutt, D.; Weizman, A.; Zhang, M.R.; Gavish, M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci., 2006, 27, 402-409.
64. Kim, K.; Moore, D.H.; Makriyannis, A.; Abood, M.E. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol., 2006, 542, 100-105.
65. Benito, C.; Romero, J.P.; Tolon, R.M.; Clemente, D.; Docagne, F.; Hillard, C.J.; Guaza, C.; Romero, J. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci., 2007, 27, 2396-2402.
66. Sapp, E.; Kegel, K.B.; Aronin, N.; Hashikawa, T.; Uchiyama, Y.; Tohyama, K.; Bhide, P.G.; Vonsattel, J.P.; Difiglia, M. Early and progressive accumulation of reactive microglia in the Huntington Disease Brain. J. Neuropathol. Exp. Neurol., 2001, 60, 161-172.
67. Sagredo, O.; Gonzalez, S.; Aroyo, I.; Pazos, M.R.; Benito, C.; Lastres-Becker, I.; Romero, J.P.; Tolon, R.M.; Mechoulam, R.; Brouillet, E.; Romero, J.; Fernández-Ruiz, J. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia, 2009, 57, 1154-1167.
68. Palazuelos, J.; Aguado, T.; Pazos, R.M.; Julien, B.; Carrasco, C.; Resel, E.; Sagredo, O.; Benito, C.; Romero, J.; Azcoitia, I.; Fernandez-Ruiz, J.; Guzman, M.; Galve-Roperh, I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain, 2009, 132, 3152-3164.
69. Chauveau, F.; Boutin, H.; Van Camp, N.; Dollé, F.; Tavitian, B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 2304-2319.
70. Turton, D.R.; Pike, V.W.; Cartoon, M.; Widdowson, D.A. Preparation of a potential marker for glia cells, (N-methyl-11C)Ro54864. J. Label. Compd. Radiopharm., 1984, 21, 1209-1210.
71. Camsonne, R.; Crouzel, C.; Comar, D.; Mazière, M.; Prenant, C.; Sastre, J.; Moulin, M.A.; Syrota A. Synthesis of N-(11C)methyl, N-(methyl-1 propyl), chloro-2-phenyl)-1 isoquinoline carboxamide-3 (PK11195): a new ligand for peripheral benzodiazepine receptors. J. Labelled Comp. Radiopharm., 1984, 21, 985-991.
72. Shah, F.; Hume, S.P.; Pike, V.W.; Ashworth, S.; McDermott, J. Synthesis of the enantiomers of [N-methyl-11C]PK11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl. Med. Biol., 1994, 21, 573-581.
73. Toyama, H.; Hatano, K.; Suzuki, H.; Ichise, M.; Momosaki, S.; Kudo, G.; Ito, F.; Kato, T.; Yamaguchi, H.; Katada, K.; Sawada, M.; Ito, K. In vivo imaging of microglial activation using a peripheral benzodiazepine receptor ligand: [11C]PK-11195 and animal PET following ethanol injury in rat striatum. Ann. Nucl. Med., 2008, 22, 417-424.
74. Visigalli, I.; Moresco, R.M.; Belloli, S.; Politi, L.S.; Gritti, A.; Ungaro, D.; Matarrese, M.; Turolla, E.; Falini, A.; Scotti, G.; Naldini, L.; Fazio, F.; Biffi, A. Monitoring disease evolution and treatment response in lysosomal disorders by the peripheral benzodiazepine receptor ligand PK11195. Neurobiol. Dis., 2009, 34, 51-62.
75. Chauveau, F.; Van Camp, N.; Dollé, F.; Kuhnast, B.; Hinnen, F.; Damont, A.; Boutin, H.; James, M.; Kassiou, M.; Tavition, B. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J. Nucl. Med., 2009, 50, 468-476.
76. Doorduin, J.; de Vries, E.F.; Dierckx, R.A.; Klein, H.C. PET imaging of the peripheral benzodiazepine receptor: monitoring disease progression and therapy response in neurodegenerative disorders. Curr. Pharm. Des., 2008, 14, 3297-3315.
77. Dollé, F.; Luus, C.; Reynolds, A.; Kassiou, M. Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. Curr. Med. Chem., 2009, 16, 2899-2923.
78. De Vries, E.F. Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation. Curr. Pharm. Des., 2006, 12, 3847-3856.
79. McCarthy, T.J.; Sheriff, A.U.; Graneto, M.J.; Talley J.J.; Welch, M.J. Radiosynthesis, in vitro validation, and in vivo evaluation of 18F-labeled COX-1 and COX-2 inhibitors. J. Nucl. Med., 2002, 43, 117-124.
80. De Vries, E.F.J.; Doorduin, J.; Dierckx, R.A.; van Waarde, A. Evaluation of [11C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nucl. Med. Biol., 2008, 35, 35-42.
81. Prabhakaran, J.; Majo, V.J.; Simpson, N.R.; Van Heertum, R.L.; Mann, J.J.; Kumar, J.S.D. Synthesis of [C-11]celecoxib: a potential PET probe for imaging COX-2 expression. J. Labelled Comp. Radiopharm., 2005, 48, 887-895.
82. De Vries, E.F.J.; van Waarde, A.; Buursma, A.R.; Vaalburg, W. Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J. Nucl. Med., 2003, 44, 1700-1706.
83. Gao, M.; Wang, M.; Miller, K.D.; Hutchins, G.D.; Zheng, Q.H. Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of neuroinflammation. Appl. Radiat. Isot., 2009, 67, 2019-2024.
84. Knuuti, J.; Bengel, F.M. Positron emission tomography and molecular imaging. Heart, 2008, 94, 360-367.
85. Van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J.R.; Raevsky, O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug. Target, 1998, 6, 151-165.
86. Dischino, D.D.; Welch, M.J.; Kilbourn, M.R.; Raichle, M.E. Relationship between lipophilicity and brain extraction of C-11 labelled radiopharmaceuticals. J. Nucl. Med., 1983, 24, 1030-1038.
87. Pike, V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharm. Sci., 2009, 30, 431-440.
88. Horti, A.G.; Van Laere, K. Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain. Curr. Pharm. Des., 2008, 14, 3363-3383.
89. Goffin, K.; Bormans, G.; Casteels, C.; Bosier, B.; Lambert, D.M.; Grachev, I.D.; Van Paesschen, W.; Van Laere, K. An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam. Neuropharmacology, 2008, 54, 1103-1106.
90. Van Laere, K.; Goffin, K.; Casteels, C.; Dupont, P.; Mortelmans, L.; de Hoon, J.; Bormans, G. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage, 2008, 39, 1533-1541.
91. Wyffels, L.; De Bruyne, S.; Blanckaert, P.; Lambert, D.M.; De Vos, F. Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH. Bioorg. Med. Chem., 2009, 17, 49-56.
92. Wyffels, L.; Muccioli, G.G.; De Bruyne, S.; Moerman, L.; Sambre, J.; Lambert, D.M.; De Vos, F. Synthesis, in vitro and in vivo evaluation, and radiolabeling of aryl anandamide analogues as candidate radioligands for in vivo imaging of fatty acid amide hydrolase in the brain. J. Med. Chem., 2009, 52, 4613-4622.
93. Bai, M.; Sexton, M.; Stella, N.; Bornhop, D.J. MBC94, a conjugable ligand for cannabinoid CB2 receptor imaging. Bioconjug. Chem., 2008, 19, 988-992.
94. Deroose, C.M.; Reumers, V.; Debyser, Z.; Baekelandt, V. Seeing genes at work in the living brain with non-invasive molecular imaging. Curr. Gene Ther., 2009, 9, 212-238.
95. Prasad, P.N. Introduction to Biophotonics. J. Wiley & Sons, inc. New Jersey, 2003, pp 265-266.
96. Padgett, L.W. Recent developments in cannabinoid ligands. Life Sci., 2005, 77, 1767-1798.
97. 9-tetrahydrocannabinol and its relationship to pharmacological potency. J. Pharmacol. Exp. Ther., 1990, 255, 624-630.
98. Charalambous, A.; Marciniak, G.; Shiue, C.Y.; Dewey, S.L.; Schlyer, D.J.; Wolf, A.P.; Makriyannis, A. Pet studies in the primate brain and biodistribution in mice using (-)-5'-18F-delta-8-THC. Pharmacol. Biochem. Behav., 1991, 40, 503-507.
99. Lu, D.; Meng, Z.; Thakur, G.A.; Fan, P.; Steed, J.; Tartal, C.L.; Hurst, D.P.; Reggio, P.H.; Deschamps, J.R.; Parrish, D.A.; George, C.; Järbe, T.U.C.; Lamb, R.J.; Makriyannis, A. Adamantyl cannabinoids: a novel class of cannabinergic ligands. J. Med. Chem., 2005, 48, 4576-4585.
100. Lavey, B.J.; Kozlowski, J.A.; Hipkin, R.W.; Gonsiorek, W.; Lundell, D.J.; Piwinski, J.J.; Narula, S.; Lunn, C.A. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorg. Med. Chem. Lett., 2005, 15, 783-786.
101. Shankar, B.B.; Lavey, B.J.; Zhou, G.; Spitler, J.A.; Tong, L.; Rizvi, R.; Yang, D.; Wolin, R.; Kozlowski, J.A.; Shih, N.; Wu, J.; Hipkin, R.W.; Gonsiorek, W.; Lunn, C.A. Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorg. Med. Chem. Lett., 2005, 15, 4417-4420.
102. Lunn, C.A.; Fine, J.S.; Rojas-Triana, A.; Jackson, J.V.; Fan, X.; Kung, T.T.; Gonsiorek, W.; Schwarz, M.A.; Lavey, B.; Kozlowski, J.A.; Narula, S.K.; Lundell, D.J.; Hipkin, R.W.; Bober, L.A. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther., 2006, 316, 780-788.
103. Gonsiorek, W.; Hesk, D.; Kinsley, D.; Chen, S.; Fine, J.S.; Jackson, J.V.; Bober, L.A.; Deno, G.; Lunn, C.A.; Kozlowski, J.A.; Lavey, B.; Piwinski, J.; Narula, S.K.; Lundell, D.J.; Hipkin, R.W. Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336. J. Biol. Chem., 2006, 281, 28143-28151.
104. Evens, N.; Bosier, B.; Lavey, B.J.; Kozlowski, J.A.; Vermaelen, P.; Baudemprez, L.; Busson, R.; Lambert, D.M.; Van Laere, K.; Verbruggen, A.M.; Bormans, G.M. Labelling and biological evaluation of [(11)C]methoxy-Sch225336: a radioligand for the cannabinoid-type 2 receptor. Nucl. Med. Biol., 2008, 35, 793-800.
105. Gallant, M.; Dufresne, C.; Gareau, Y.; Guay, D.; Leblanc, Y.; Prasit, P.; Rochette, C.; Sawyer, N.; Slipetz, D.M.; Tremblay, N.; Metters, K.M.; Labelle, M. New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg. Med. Chem. Lett., 1996, 6, 2263-2268.
106. Valenzano, K.J.; Tafesse, L.; Lee, G.; Harrison, J.E.; Boulet, J.M.; Gottshall, S.L.; Mark, L.; Pearson, M.S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S.M.; Turchin, P.I.; Elsemore, D.A.; Toth, M.; Koetzner, L.; Whiteside, G.T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology, 2005, 48, 658-672.
107. LaBuda, C.J.; Koblish, M.; Little, P.J. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur. J. Pharmacol., 2005, 527, 172-174.
108. Whiteside, G.T.; Gottshall, S.L.; Boulet, J.M.; Chaffer, S.M.; Harrison, J.E.; Pearson, M.S.; Turchin, P.I.; Mark, L.; Garrison, A.E.; Valenzano K.J. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur. J. Pharmacol., 2005, 528, 65-72.
109. Hu, B.; Doods, H.; Treede, R.D.; Ceci, A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain, 2009, 143, 206-212.
110. Leichsenring, A.; Andriske, M.; Bäcker, I.; Stichel, C.C.; Lübbert, CH. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiedebergs Arch. Pharmacol., 2009, 379, 627-636.
111. Mancini, I.; Brusa, R.; Quadrato, G.; Foglia, C.; Scandroglio, P.; Silverman, L.S.; Tulshian, D.; Reggiani, A.; Beltramo, M. Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Brit. J. Pharmacol., 2009, 158, 382-391.
112. Giblin, G.M.P.; O'Shaughnessy, C.T.; Naylor, A.; Mitchell, W.L.; Eatherton, A.J.; Slingsby, B.P.; Rawlings, D.A.; Goldsmith, P.; Brown, A.J.; Haslam, C.P.; Clayton, N.M.; Wilson, A.W.; Chessell, I.P.; Wittington, A.R.; Green, R. Discovery of 2-[(2,4-dichloro-phenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoro-methyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J. Med. Chem., 2007, 50, 2597-2600.
113. http://clinicaltrials.gov/; accessed august 2009
114. Rinaldi-Carmona, M.; Barth, F.; Heaulme, F.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D.; Ferrara, P.; Soubrie, P.; Breliere, J.C.; Le Fur, G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 1994, 350, 240-244.
115. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J.M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, M.; Portier, M.; Shire, D.; Breliere, J.C.; Le Fur, G. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 1998, 284, 644-650.
116. Mussinu, J.; Ruiu, S.; Mulè, A.C.; Pau, A.; Carai, M.A.; Loriga, G.; Murineddu, G.; Pinna, G.A. Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg. Med. Chem., 2003, 11, 251-263.
117. Mathews, W.B.; Scheffel, U.; Finley, P.; Ravert, H.T.; Frank, R.A.; Rinaldi-Carmona, M.; Barth, F.; Dannals, R.F. Biodistribution of [18F]SR144385 and [18F]SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nucl. Med. Biol., 2000, 27, 757-762.
118. Hostetler, E.D.; Terry, G.E.; Burns, H.D. An improved synthesis of substituted [11C]toluenes via Suzuki coupling with [11C]methyl iodide. J. Labelled Comp. Radiopharm., 2005, 48, 629-634.
119. Inaba, T.; Kaya, T.; Iwamura, H. 2-oxoquinoline compounds and medicinal uses thereof. WO Patent, 2000, WO/2000/040562.
120. Iwamura, H.; Suzuki, H.; Ueda, Y.; Kaya, T.; Inaba, T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther., 2001, 296, 420-425.
121. Ueda, Y.; Miyagawa, N.; Matsui, T.; Kaya, T.; Iwamura, H. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur. J. Pharmacol., 2005, 520, 164-171.
122. Maekawa, T.; Nojima, H.; Kuraishi, Y.; Aisaka, K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur. J. Pharmacol., 2006, 542, 179-183.
123. Raitio, K.H.; Savinainen, J.R.; Nevalainen, T.; Järvinen, T.; Vepsäläinen, J. Synthesis and in vitro evaluation of novel 2-oxo-1,2-dihydroquinoline CB2 receptor inverse agonists. Chem. Biol. Drug Des., 2006, 68, 334-340.
124. Evens, N.; Muccioli, G.G.; Houbrechts, N.; Lambert, D.M.; Verbruggen, A.M.; Van Laere, K.; Bormans, G.M. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging. Nucl. Med. Biol., 2009, 36, 455-465.
125. Muccioli, G.G.; Lambert, D.M. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr. Med. Chem., 2005, 12, 1361-1394.
126. Manera, C.; Cascio, M.G.; Benetti, V.; Allarà, M.; Tuccinardi, T.; Martinelli, A.; Saccomanni, G.; Vivoli, E.; Ghelardini, C.; Di Marzo, V.; Ferrarini, P.L. New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg. Med. Chem. Lett., 2007, 17, 6505-6510.
127. Stern, E.; Muccioli, G.G.; Bosier, B.; Hamtiaux, L.; Millet, R.; Poupaert, J.H.; Hénichart, J.P.; Depreux, P.; Goossens, J.F.; Lambert, D.M. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality. J. Med. Chem., 2007, 50, 5471-5484.
128. Stern, E.; Muccioli, G.G.; Millet, R.; Goossens, J.; Farce, A.; Chavatte, P.; Poupaert, J.H.; Lambert, D.M.; Depreux, P.; Hénichart, J. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J. Med. Chem., 2006, 49, 70-79.
129. Pasquini, S.; Botta, L.; Semeraro, T.; Mugnaini, C.; Ligresti, A.; Palazzo, E.; Maione, S.; Di Marzo, V.; Corelli, F. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. J. Med. Chem., 2008, 51, 5075-5084.
130. Pagé, D.; Balaux, E.; Boisvert, L.; Ziping, L.; Milburn, C.; Tremblay, M.; Wei, Z.; Woo, S.; Luo, X.; Cheng, Y.; Yang, H.; Srivastava, S.; Zhou, F.; Brown, W.; Tomaszewski, M.; Walpole, C.; Hodzic, L.; St-Onge, S.; Godbout, C.; Salois, D.; Payza, K. Novel benzimidazole derivatives as selective CB2 agonists. Bioorg. Med. Chem. Lett., 2008, 18, 3695-3700.
131. Omura, H.; Kawai, M.; Shima, A.; Iwata, Y.; Ito, F.; Masuda, T.; Ohta, A.; Makita, N.; Omoto, K.; Sugimoto, H.; Kikuchi, A.; Iwata, H.; Ando, K. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives. Bioorg. Med. Chem. Lett., 2008, 18, 3310-3314.
132. Kikuchi, A.; Ohashi, K.; Sugie, Y.; Sugimoto, H.; Omura, H. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J. Pharmacol. Sci., 2008, 106, 219-224.
133. Cheng, Y.; Albrecht, B.K.; Brown, J.; Buchanan, J.L.; Buckner, W.H.; DiMauro, E.F.; Emkey, R.; Fremeau, R.T.; Harmange, J.; Hoffman, B.J.; Huang, L.; Huang, M.; Lee, J.H.; Lin, F.; Martin, M.W.; Nguyen, H.Q.; Patel, V.F.; Tomlinson, S.A.; White, R.D.; Xia, X.; Hitchcock, S.A. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists. J. Med. Chem., 2008, 51, 5019-5034.
134. Chu, G.; Saeui, C.T.; Worm, K.; Weaver, D.G.; Goodman, A.J.; Broadrup, R.L.; Cassel, J.A.; DeHaven, R.N.; LaBuda, C.J.; Koblish, M.; Brogdon, B.; Smith, S.; Le Bourdonnec, B.; Dolle, R.E. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists. Bioorg. Med. Chem. Lett., 2009, 19, 5931-5935.
135. Bhattacharjee, H.; Gurley, S.N.; Moore, B.M. Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands. Bioorg. Med. Chem. Lett., 2009, 19, 1691-1693.
136. Worm, K.; Weaver, D.G.; Green, R.C.; Saeui, C.T.; Dulay, D.S.; Barker, W.M.; Cassel, J.A.; Stabley, G.J.; DeHaven, R.N.; LaBuda, C.J.; Koblish, M.; Brogdon, B.L.; Smith, S.A.; Dolle, R.E. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Bioorg. Med. Chem. Lett., 2009, 19, 5004-5008.
137. Frost, J.J.; Wagner, H.N. Jr.; Dannals, R.F.; Ravert, H.T.; Links, J.M.; Wilson, A.A.; Burns, H.D.; Wong, D.F.; McPherson, R.W.; Rosenbaum, A.E.; Kuhar, M.J.; Snyder, S.H. Imaging opiate receptors in the human brain by positron tomography. J. Comput. Assist. Tomogr., 1985, 9, 231-236.
138. Burns, H.D.; Van Laere, K.; Sanabria-Bohorquez, S.; Hamill, T.G.; Bormans, G.; Eng, W.S.; Gibson, R.; Ryan, C.; Connolly, B.; Patel, S.; Krause, S.; Vanko, A.; Van Hecken, A.; Dupont, P.; De Lepeleire, I.; Rothenberg, P.; Stoch, S.A.; Cote, J.; Hagmann, W.K.; Jewell, J.P.; Lin, L.S.; Liu, P.; Goulet, M.T.; Gottesdiener, K.; Wagner, J.A.; de Hoon, J.; Mortelmans, L.; Fong, T.M.; Hargreaves, R.J. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. USA, 2007, 104, 9800-9805.
139. Hall, H.; Wedel, I.; Halldin, C.; Kopp, J.; Farde, L. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes. J. Neurochem., 1990, 55, 2048-2057.
140. Elsinga, P.H.; Hatano, K.; Ishiwata, K. PET tracers for imaging of the dopaminergic system. Curr. Med. Chem., 2006, 13, 2139-2153.
141. Mukherjee, J.; Yang, Z.Y.; Das, M.K.; Brown, T. Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl. Med. Biol., 1995, 22, 283-296.
142. Verbist, B.M.P.; De Cleyn, M.A.J.; Surkyn, M.; Fraiponts, E.; Aerssens, J.; Nijsen, M.J.M.A.; Gijsen, H.J.M. 5-sulfonyl-benimidazoles as selective CB2 agonists. Bioorg. Med. Chem. Lett., 2008, 18, 2574-2579.
143. Ashton, J.C.; Wright, J.L.; McPartland, J.M.; Tyndall, J.D.A. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr. Med. Chem., 2008, 15, 1428-1443.
144. Khanolkar, A.D.; Lu, D.; Ibrahim, M.; Duclos, R.I.; Thakur, G.A.; Malan, T.P.; Porreca, F.; Veerappan, V.; Tian, X.; George, C.; Parrish, D.A.; Papahatjis, D.P.; Makriyannis, A. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J. Med. Chem., 2007, 50, 6493-6500.
145. Rhee, M.H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; Mechoulam, R. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J. Med. Chem., 1997, 40, 3228-3233.
146. Doorduin, J.; Klein, H.C.; Dierckx, R.A.; James, M.; Kassiou, M.; de Vries, E.F.J. [11C]-DPA-173 and [18F]-DPA-714 as new PET tracers for TPSO: a comparison with [11C]-(R)-PK11195 in a rat model of herpes encephalitis. Mol. Imaging Biol., 2009, 11, 386-398.
147. Kenakin, T. Principles: receptor theory in pharmacology. Trends Pharmacol. Sci., 2004, 25, 186-192.
148. Bouaboula, M.; Dussossoy, D.; Casellas, P. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR144528. J. Biol. Chem., 1999, 274, 20397-20405.
149. Pertwee, R.G. Inverse agonism at cannabinoid receptors. Int. Congr. Series, 2003, 1249, 75-86.
150. Wilson, J.; Lin, H.; Fu, D.; Javitch, J.A.; Strange, P.G. Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. J. Neurochem., 2001, 77, 493-504.
151. Kenakin, T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol., 2004, 65, 2-11.